Literature DB >> 17873301

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations.

Jane Ahlqvist-Rastad1, Maria Albertsson, Jonas Bergh, Gunnar Birgegård, Peter Johansson, Bertil Jonsson, Elisabeth Kjellen, Sven Påhlman, Björn Zackrisson, Anders Osterborg.   

Abstract

Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17873301     DOI： 10.1007/s12032-007-0037-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  15 in total

1.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

2.  Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study.

Authors:  Anders Osterborg; Yvonne Brandberg; Michael Hedenus
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

3.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

Authors:  Michael Henke; Dominik Mattern; Margaret Pepe; Christina Bézay; Christian Weissenberger; Martin Werner; Frank Pajonk
Journal:  J Clin Oncol       Date:  2006-10-10       Impact factor: 44.544

5.  Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials.

Authors:  Michael Hedenus; Johan Vansteenkiste; Dusan Kotasek; Matthew Austin; Rafael G Amado
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

6.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Authors:  James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gord S Okawara; Mark N Levine
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

7.  Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies.

Authors:  Parviz Kokhaei; Amir Osman Abdalla; Lotta Hansson; Eva Mikaelsson; Manfred Kubbies; Anton Haselbeck; Helena Jernberg-Wiklund; Håkan Mellstedt; Anders Osterborg
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

8.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

Authors:  Michael Henke; Roland Laszig; Christian Rübe; Ulrich Schäfer; Klaus-Dieter Haase; Burkhard Schilcher; Stephan Mose; Karl T Beer; Ulrich Burger; Chris Dougherty; Hermann Frommhold
Journal:  Lancet       Date:  2003-10-18       Impact factor: 79.321

9.  Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Authors:  Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

10.  Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis.

Authors:  M Aapro; B Coiffier; J Dunst; A Osterborg; H U Burger
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640
View more
  2 in total

1.  1 RBC Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Erythropoietin for cancer-associated malignant anemia: A meta-analysis.

Authors:  Feng Zhao; Yijuan Wang; Lin Liu; Meiling Bian
Journal:  Mol Clin Oncol       Date:  2017-05-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.